Brazil’s health regulator has approved five new semaglutide injection pens for diabetes treatment, intensifying competition against Novo Nordisk as the molecule’s patent expired in March 2026.

PHARMA · JULY 30, 2026 · LATIN AMERICA
Five new semaglutide injection pens cleared by Anvisa, Brazil’s national health surveillance agency, for the treatment of diabetes — a regulatory development that lands less than four months after the molecule’s patent expired in Brazil in March 2026, according to Folha de S.Paulo. The approvals expand the competitive field in a market that, until recently, Novo Nordisk held under near-exclusive commercial control through Ozempic and Wegovy.
The timing matters. Alanac, Brazil’s association of domestic pharmaceutical manufacturers, estimates that national laboratories could capture between 40% and 50% of combined unit sales of liraglutide and semaglutide within three years, either through proprietary products or manufacturing partnerships, according to Valor Econômico. Liraglutide and semaglutide together generated R$5.7 billion in Brazilian sales in 2024, per the same source. That is the revenue base now exposed to generic-driven price compression.
EMS, the domestic pharmaceutical group controlled by Carlos Sanchez, is currently the only Brazilian manufacturer with Anvisa authorization to produce and sell pens for both molecules, according to Valor Econômico. Its 2024 revenue reached R$8.26 billion, growing 20% year-on-year, per Exame — a financial position that could support the manufacturing scale-up the GLP-1 analog market will require. The company has projected R$1 billion in capital investment over two years, according to Exame, and plans to expand its research and development team from 800 to 1,000 people by 2026.
The rivaroxaban precedent, cited by Alanac president Henrique Tada in Valor Econômico, is instructive. After the patent on Bayer’s anticoagulant Xarelto expired, sales volume rose 90% and the average price fell to roughly one-third of the original level; generic and similar versions now account for more than 90% of units sold and nearly 70% of revenue. If that pattern approximates what unfolds for semaglutide, the market’s structural ceiling is access-driven rather than demand-driven — meaning volume projections may prove conservative even as average selling prices decline sharply.
Itaú BBA, the investment bank, estimates the GLP-1 analog segment closed 2025 at around R$10 billion and could reach R$50 billion by 2030, according to Valor Econômico. BTG Pactual separately estimates the Brazilian GLP-1 market — combining obesity and diabetes indications — could surpass R$17 billion in 2026 alone, representing roughly one quarter of projected total pharmaceutical retail growth for the year, according to Exame. Both figures are bank projections, not official data, and carry the uncertainty inherent in a market undergoing rapid structural change.
The principal friction is supply, not approval. A cleared Anvisa registration does not equal a stocked pharmacy shelf. Grazielle Alves, senior manager at EY-Parthenon, notes that industry projections point to 10.6% revenue growth for Brazil’s pharmaceutical sector in 2026 relative to 2025, according to Valor Econômico — but that aggregate figure masks the operational bottleneck specific to injectable biologics: pen manufacturing requires specialized fill-finish capacity that cannot be repurposed overnight from oral solid-dose lines. Alanac’s own estimate conditions the 40–50% market-share scenario on the pace of Anvisa approvals and on manufacturers’ ability to bring supply to market at scale. The five pens cleared in this round represent regulatory access; commercial access depends on distribution infrastructure that press materials do not detail.
Novo Nordisk’s response is also a variable the available record does not yet resolve. The company has initiated legal action against EMS, according to Valor Econômico, though the nature, status, and scope of that proceeding have not been fully disclosed in public sources reviewed for this article. The matter is pending resolution, and no finding has been issued. How that litigation proceeds could affect the competitive timeline for at least one domestic entrant, independent of Anvisa’s approval calendar.
What to Watch
- The pace at which the five newly approved semaglutide pens reach pharmacy shelves and enter state procurement tenders, particularly in São Paulo and Minas Gerais
- The outcome of Novo Nordisk’s legal action against EMS, which could affect the domestic competitive timeline
- Whether additional domestic manufacturers beyond EMS receive Anvisa authorization, which would accelerate the price-compression dynamic Alanac projects
The deeper signal is structural: Brazil’s pharmaceutical retail market, which Abrafarma, the pharmacy-chain association, reported at R$103.14 billion in large-chain revenue for 2024, is large enough that even a partial shift in GLP-1 pricing dynamics would register materially across the supply chain — from manufacturer margins to pharmacy mix to health-plan formulary costs. The five approvals are a regulatory event; the commercial reckoning is still being priced in.
Brazil’s GLP-1 Market Trajectory
Context: Semaglutide patent expires March 2026. Combined liraglutide + semaglutide sales reached R$5.7 billion in 2024. Alanac projects 40–50% domestic market share (liraglutide + semaglutide units) over a 3-year horizon. Brazilian pharma revenue is projected to grow 10.6% in 2026 versus 2025.
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







